Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose
Condition(s):Healthy SubjectsLast Updated:November 1, 2019Completed
Hide Studies Not Open or Pending
Condition(s):Healthy SubjectsLast Updated:November 1, 2019Completed
Condition(s):Endovascular Infection; Bone and Joint Infection; Skin and Soft Tissue Infection; Pulmonary Infection; Gastrointestinal Infection; Genitourinary InfectionLast Updated:December 12, 2023Enrolling by invitation
Condition(s):HealthyLast Updated:June 16, 2014Completed
Condition(s):DyslipidemiaLast Updated:April 10, 2015Completed
Condition(s):HealthyLast Updated:November 14, 2017Completed
Condition(s):COPD Exacerbation AcuteLast Updated:May 10, 2021Completed
Condition(s):Hepatitis CLast Updated:May 6, 2013Completed
Condition(s):Healthy SubjectsLast Updated:June 13, 2012Completed
Condition(s):Helicobacter InfectionsLast Updated:April 10, 2018Unknown status
Condition(s):Helicobacter InfectionLast Updated:April 18, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.